Arcadia Biosciences is no longer an agricultural-trait company. It is a Dallas seller of Zola coconut water trying to keep a Nasdaq listing after a reverse-merger partner walked away and after two summer financings rebuilt cash by issuing a thick stack of preferred investment options. The June quarter did not show the growth story management is selling. Revenue was essentially unchanged from the year-ago period because inventory ran short and ships arrived late. The operating company still lost money, but cash used in operations shrank to a few hundred thousand, which is the only encouraging operating fact in the print.
The tension sits between a thinner cost base and a capital structure that is eating the residual claim. Selling, general, and administrative expense fell by $1 million versus the year-ago quarter, to what management calls an all-time low. Cash finished the quarter at $4 million after a June private placement that raised the same amount of gross proceeds. Headline loss attributable to common stockholders was $6 million, driven by a valuation charge on the June placement, a mark on the Above Food stake that is now carried at zero, and offering costs. Book equity ended at $633 thousand, which sits below the Nasdaq Capital Market stockholders-equity floor.
July sell-through is the claim that has to do the work the June quarter did not. Management said monthly Zola sales topped $740 thousand in July. Those sales passed $1 million through the first week of August, more than half of the entire second-quarter revenue print. A one liter espresso SKU is planned for the fourth quarter with pre-launch commitments from the two largest customers, and three more products are planned for the first half of next year. The open question is whether that restock and SKU calendar can fund the brand before the exchange forces another recapitalization.